Gilead Sciences (NASDAQ:GILD) was upgraded by stock analysts at Citigroup from a “neutral” rating to a “buy” rating in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage currently has a $66.80 target price on the biopharmaceutical company’s stock. Citigroup‘s target price would suggest a potential downside of 0.55% from the stock’s previous close.
GILD has been the topic of several other reports. Oppenheimer set a $85.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, April 22nd. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Mizuho set a $88.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday, March 22nd. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, February 7th. Finally, Wells Fargo & Co dropped their price objective on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, February 5th. Nine research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $80.57.
Shares of NASDAQ:GILD opened at $67.17 on Wednesday. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $84.81 billion, a P/E ratio of 10.92, a P/E/G ratio of 0.81 and a beta of 1.14. Gilead Sciences has a fifty-two week low of $60.32 and a fifty-two week high of $79.61.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.53 by $0.23. The company had revenue of $5.28 billion for the quarter, compared to the consensus estimate of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.48 EPS. On average, analysts expect that Gilead Sciences will post 6.6 EPS for the current year.
In other news, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total transaction of $173,178.00. Following the sale, the director now directly owns 57,560 shares in the company, valued at $3,691,898.40. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the sale, the director now owns 34,669 shares in the company, valued at $2,270,126.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,602 shares of company stock worth $1,863,445. Company insiders own 0.20% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Athena Capital Advisors LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $27,000. Capital Financial Planning LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $27,000. Creative Financial Designs Inc. ADV increased its position in shares of Gilead Sciences by 55.9% in the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 165 shares during the last quarter. Claybrook Capital LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $32,000. Finally, Trustcore Financial Services LLC bought a new position in shares of Gilead Sciences in the first quarter worth approximately $34,000. Hedge funds and other institutional investors own 78.68% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: Cryptocurrencies
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.